Quinaprilat hydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526074

CAS#: 1435786-09-6 (hydrate)

Description: Quinaprilat is the active metabolite of quinapril, an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure.


Chemical Structure

img
Quinaprilat hydrate
CAS# 1435786-09-6 (hydrate)

Theoretical Analysis

MedKoo Cat#: 526074
Name: Quinaprilat hydrate
CAS#: 1435786-09-6 (hydrate)
Chemical Formula: C23H28N2O6
Exact Mass: 0.00
Molecular Weight: 410.470
Elemental Analysis: C, 64.47; H, 6.59; N, 6.54; O, 22.40

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1435786-09-6 (hydrate)   82768-85-2 (anhydrous)    

Synonym: Quinaprilat; BRN 5653070; CI 928; CI-928.

IUPAC/Chemical Name: (S)-2-(((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrate

InChi Key: OFYSYEOWQQCPEU-ZAFWUOJLSA-N

InChi Code: InChI=1S/C23H26N2O5.H2O/c1-15(24-19(22(27)28)12-11-16-7-3-2-4-8-16)21(26)25-14-18-10-6-5-9-17(18)13-20(25)23(29)30;/h2-10,15,19-20,24H,11-14H2,1H3,(H,27,28)(H,29,30);1H2/t15-,19-,20-;/m0./s1

SMILES Code: O=C([C@H]1N(C([C@@H](N[C@H](C(O)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=CC=C3)C1)O.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: Quinaprilat hydrate mediates the interaction of organic anion transporter 3 (hOAT3) which can promote renal active secretion of quinapril that increases uptake of quinaprilat to 25-fold in HEK293 cells. Quinaprilat hydrate can inhibit the activity of protein kinase C (PKC) by activing the B1 receptor resulting in the release of NO in human lung microvascular endothelial (HLMVE) cells.
In vitro activity: This study examined the effects of propofol (50 μM), quinaprilat and enalaprilat (10-5 M) on fibrinolysis, oxidative stress parameters, and nitric oxide bioavailability in human umbilical vein endothelial cells (HUVECs). These findings suggest that the studied angiotensin-converting enzyme inhibitors exerted protective effects against endothelial cell dysfunction caused by propofol, independently of hemodynamics. Reference: J Renin Angiotensin Aldosterone Syst. 2017 Jan;18(1):1470320316687197. https://pubmed.ncbi.nlm.nih.gov/28090801/
In vivo activity: Angiotensin converting enzyme (ACE) inhibitors, including quinapril, improve survival and quality of life in human patients and small animals with cardiovascular and renal disease. There is limited information regarding their effects in healthy, mature horses. Quinaprilat was detected in all horses following oral administration of quinapril; however, it was below the limit of quantification of the assay for most horses in the 120 mg dosing group. These results suggest that quinapril has sufficient oral absorption to produce inhibition of ACE in healthy horses. provides a potential treatment for horses with cardiovascular and renal disease. Reference: Equine Vet J. 2014 Nov;46(6):729-33. https://pubmed.ncbi.nlm.nih.gov/24175935/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 0.0 0.00

Preparing Stock Solutions

The following data is based on the product molecular weight 410.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Wojewodzka-Zelezniakowicz M, Gromotowicz-Poplawska A, Kisiel W, Konarzewska E, Szemraj J, Ladny JR, Chabielska E. Angiotensin-converting enzyme inhibitors attenuate propofol-induced pro-oxidative and antifibrinolytic effect in human endothelial cells. J Renin Angiotensin Aldosterone Syst. 2017 Jan;18(1):1470320316687197. doi: 10.1177/1470320316687197. PMID: 28090801; PMCID: PMC5843862. 2. Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. PMID: 18713951. 3. Davis JL, Kruger K, LaFevers DH, Barlow BM, Schirmer JM, Breuhaus BA. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses. Equine Vet J. 2014 Nov;46(6):729-33. doi: 10.1111/evj.12206. Epub 2014 Jan 7. PMID: 24175935. 4. van Beusekom HM, Ferrero V, Ribichini F, van der Giessen WJ. Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries. Atherosclerosis. 2009 Jul;205(1):120-5. doi: 10.1016/j.atherosclerosis.2008.11.029. Epub 2008 Dec 6. PMID: 19135197.
In vitro protocol: 1. Wojewodzka-Zelezniakowicz M, Gromotowicz-Poplawska A, Kisiel W, Konarzewska E, Szemraj J, Ladny JR, Chabielska E. Angiotensin-converting enzyme inhibitors attenuate propofol-induced pro-oxidative and antifibrinolytic effect in human endothelial cells. J Renin Angiotensin Aldosterone Syst. 2017 Jan;18(1):1470320316687197. doi: 10.1177/1470320316687197. PMID: 28090801; PMCID: PMC5843862. 2. Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. PMID: 18713951.
In vivo protocol: 1. Davis JL, Kruger K, LaFevers DH, Barlow BM, Schirmer JM, Breuhaus BA. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses. Equine Vet J. 2014 Nov;46(6):729-33. doi: 10.1111/evj.12206. Epub 2014 Jan 7. PMID: 24175935. 2. van Beusekom HM, Ferrero V, Ribichini F, van der Giessen WJ. Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries. Atherosclerosis. 2009 Jul;205(1):120-5. doi: 10.1016/j.atherosclerosis.2008.11.029. Epub 2008 Dec 6. PMID: 19135197.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Davis JL, Kruger K, LaFevers DH, Barlow BM, Schirmer JM, Breuhaus BA. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses. Equine Vet J. 2014 Nov;46(6):729-33. doi: 10.1111/evj.12206. Epub 2014 Jan 7. PubMed PMID: 24175935.

2: Kieback AG, Felix SB, Reffelmann T. Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. Review. PubMed PMID: 19761414.

3: Sora I, Cristea E, Albu F, Udrescu S, David V, Medvedovici A. LC-MS/MS assay of quinapril and its metabolite quinaprilat for drug bioequivalence evaluation: prospective, concurrential and retrospective method validation. Bioanalysis. 2009 Apr;1(1):71-86. doi: 10.4155/bio.09.5. PubMed PMID: 21083190.

4: van Beusekom HM, Ferrero V, Ribichini F, van der Giessen WJ. Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries. Atherosclerosis. 2009 Jul;205(1):120-5. doi: 10.1016/j.atherosclerosis.2008.11.029. Epub 2008 Dec 6. PubMed PMID: 19135197.

5: Dasandi B, Shah S; Shivprakash. Determination of quinapril and quinaprilat in human plasma by ultraperformance liquid chromatography-electrospray ionization mass spectrometry. Biomed Chromatogr. 2009 May;23(5):492-8. doi: 10.1002/bmc.1143. PubMed PMID: 19016233.

6: Parekh SA, Pudage A, Joshi SS, Vaidya VV, Gomes NA, Kamat SS. Simultaneous determination of hydrochlorothiazide, quinapril and quinaprilat in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 15;873(1):59-69. doi: 10.1016/j.jchromb.2008.07.046. Epub 2008 Aug 7. PubMed PMID: 18723407.

7: Kieback AG, Grohmann A, Baumann G, Felix SB. Haemodynamic effects of intravenous quinaprilat in comparison to sodium nitroprusside in patients with chronic heart failure. Int J Cardiol. 2007 Sep 14;121(1):102-4. Epub 2006 Nov 13. PubMed PMID: 17098309.

8: Steinhauff S, Pehlivanli S, Bakovic-Alt R, Meiser BM, Becker BF, von Scheidt W, Weis M. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. Transplantation. 2004 Jun 27;77(12):1859-65. PubMed PMID: 15223904.

9: Kwapisz MM, Müller M, Schindler E, Demir S, Veit M, Roth P, Hempelmann G. The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery. J Cardiothorac Vasc Anesth. 2004 Feb;18(1):53-8. PubMed PMID: 14973800.

10: Appenroth D, Beutinger R, Lupp A, Fleck C. Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy. Exp Toxicol Pathol. 2003 Jun;54(5-6):359-66. PubMed PMID: 12877346.

11: Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T. Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull. 2003 Jun;26(6):872-5. PubMed PMID: 12808303.

12: Chen X, Minatoguchi S, Wang N, Arai M, Lu C, Uno Y, Misao Y, Takemura G, Fujiwara H. Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits. J Cardiovasc Pharmacol. 2003 Jun;41(6):938-45. PubMed PMID: 12775974.

13: Hayase N, Satomi M, Hara A, Awaya T, Shimizu K, Matsubara K. Protective effects of quinaprilat and trandolaprilat, active metabolites of quinapril and trandolapril, on hemolysis induced by lysophosphatidylcholine in human erythrocytes. Biol Pharm Bull. 2003 May;26(5):712-6. PubMed PMID: 12736518.

14: Lazar HL. Quinaprilat during cardioplegic arrest. J Thorac Cardiovasc Surg. 2003 Apr;125(4):974-5. PubMed PMID: 12698173.

15: Korn P, Kröner A, Schirnhofer J, Hallström S, Bernecker O, Mallinger R, Franz M, Gasser H, Wolner E, Podesser BK. Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2002 Aug;124(2):352-60. PubMed PMID: 12167796.

16: Abbara Ch, Aymard G, Hinh S, Diquet B. Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 25;766(2):199-207. PubMed PMID: 11824807.

17: Prieto JA, Alonso RM, Jiménez RM. Determination of the angiotensin-converting enzyme inhibitor quinapril and its metabolite quinaprilat in pharmaceuticals and urine by capillary zone electrophoresis and solid-phase extraction. Electrophoresis. 2002 Jan;23(1):102-9. PubMed PMID: 11824610.

18: Begg EJ, Robson RA, Gardiner SJ, Hudson LJ, Reece PA, Olson SC, Posvar EL, Sedman AJ. Quinapril and its metabolite quinaprilat in human milk. Br J Clin Pharmacol. 2001 May;51(5):478-81. PubMed PMID: 11422007; PubMed Central PMCID: PMC2014479.

19: Prieto JA, Alonso RM, Jiménez RM, Blanco A. Solid-phase extraction and high-performance liquid chromatography applied to the determination of quinapril and its metabolite quinaprilat in urine. J Chromatogr Sci. 2001 Apr;39(4):153-9. PubMed PMID: 11318067.

20: Houben AJ, Kroon AA, de Haan CH, Fuss-Lejeune MJ, de Leeuw PW. Quinaprilat-induced vasodilatation in forearm vasculature of patients with essential hypertension: comparison with enalaprilat. Cardiovasc Drugs Ther. 2000 Dec;14(6):657-63. PubMed PMID: 11300367.